Millendo Therapeutics (MLND) Stock Analysis

What Millendo Therapeutics does

Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.

Key metrics

ETFs linked to MLND

Broad-market and Healthcare sector ETFs an investor holding Millendo Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MLND fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Millendo Therapeutics?

Millendo Therapeutics trades under the ticker MLND on NASDAQ.

Which exchange is MLND listed on?

MLND is listed on NASDAQ.

What sector does Millendo Therapeutics operate in?

Millendo Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MLND in a portfolio?

PortView shows MLND's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.